Literature DB >> 21822297

Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy.

Thanh-Nhan Nguyen-Pham1, Deok-Hwan Yang, Truc-Anh Thi Nguyen, Mi-Seon Lim, Cheol Yi Hong, Mi-Hyun Kim, Hyun Ju Lee, Youn-Kyung Lee, Duck Cho, Soo-Young Bae, Jae-Sook Ahn, Yeo-Kyeoung Kim, Ik-Joo Chung, Hyeoung-Joon Kim, Je-Jung Lee.   

Abstract

Dendritic cell (DC)-based vaccines continue to be considered an attractive tool for cancer immunotherapy. DCs require an additional signal from the environment or other immune cells to polarize the development of immune responses toward T helper 1 (Th1) or Th2 responses. DCs play a role in natural killer (NK) cell activation, and NK cells are also able to activate and induce the maturation of DCs. We investigated the types of NK cells that can induce the maturation and enhanced function of DCs and the conditions under which these interactions occur. DCs that were activated by resting NK cells in the presence of inflammatory cytokines exhibited increased expression of several costimulatory molecules and an enhanced ability to produce IL-12p70. NK cell-stimulated DCs potently induced Th1 polarization and exhibited the ability to generate tumor antigen-specific cytotoxic T lymphocyte responses. Our data demonstrate that functional DCs can be generated by coculturing immature DCs with freshly isolated resting NK cells in the presence of Toll-like receptor agonists and proinflammatory cytokines and that the resulting DCs effectively present antigens to induce tumor-specific T-cell responses, which suggests that these cells may be useful for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21822297      PMCID: PMC4002926          DOI: 10.1038/cmi.2011.23

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  33 in total

Review 1.  T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal.

Authors:  P Kaliński; C M Hilkens; E A Wierenga; M L Kapsenberg
Journal:  Immunol Today       Date:  1999-12

2.  Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction.

Authors:  P L Vieira; E C de Jong; E A Wierenga; M L Kapsenberg; P Kaliński
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

3.  CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal.

Authors:  O Schulz; A D Edwards; M Schito; J Aliberti; S Manickasingham; A Sher; C Reis e Sousa
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

Review 4.  Type I interferons and T helper development.

Authors:  J D Farrar; K M Murphy
Journal:  Immunol Today       Date:  2000-10

Review 5.  Dendritic cell regulation of TH1-TH2 development.

Authors:  M Moser; K M Murphy
Journal:  Nat Immunol       Date:  2000-09       Impact factor: 25.606

6.  Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.

Authors:  Thanh Nhan Nguyen Pham; Cheol Yi Hong; Jung-Joon Min; Joon-Haeng Rhee; Truc Anh Thi Nguyen; Byoung Chul Park; Deok-Hwan Yang; Young-Kyu Park; Hyeong-Rok Kim; Ik-Joo Chung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Exp Mol Med       Date:  2010-06-30       Impact factor: 8.718

7.  Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells.

Authors:  Deok-Hwan Yang; Mi-Hyun Kim; Cheol Yi Hong; Youn-Kyung Lee; Chun-Ji Jin; Thanh-Nhan Nguyen Pham; Jae-Sook Ahn; Woo-Kyun Bae; Yeo-Kyeoung Kim; Ik-Joo Chung; Hyeoung-Joon Kim; Pawel Kalinski; Je-Jung Lee
Journal:  Ann Hematol       Date:  2010-03-18       Impact factor: 3.673

8.  Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens.

Authors:  Sang-Ki Kim; Thanh-Nhan Nguyen Pham; Tuyet Minh Nguyen Hoang; Hyun-Kyu Kang; Chun-Ji Jin; Jong-Hee Nam; Sang-Young Chung; So-Jin-Na Choi; Deok-Hwan Yang; Yeo-Kyeoung Kim; Ik-Joo Chung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Ann Hematol       Date:  2009-03-11       Impact factor: 3.673

9.  Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates.

Authors:  Je-Jung Lee; Bo-Hwa Choi; Hyun-Kyu Kang; Myong-Suk Park; Jung-Sun Park; Sang-Ki Kim; Thanh-Nhan Nguyen Pham; Duck Cho; Jong-Hee Nam; Young-Jin Kim; Joon-Haeng Rhee; Deok-Hwan Yang; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Ik-Joo Chung
Journal:  Leuk Lymphoma       Date:  2007-10

10.  Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation.

Authors:  Ravikumar Muthuswamy; Julie Urban; Je-Jung Lee; Todd A Reinhart; David Bartlett; Pawel Kalinski
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

View more
  9 in total

Review 1.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

Review 2.  NK cells in immunotolerant organs.

Authors:  Haoyu Sun; Cheng Sun; Zhigang Tian; Weihua Xiao
Journal:  Cell Mol Immunol       Date:  2013-04-08       Impact factor: 11.530

Review 3.  Natural killer cells: a promising immunotherapy for cancer.

Authors:  Junfeng Chu; Fengcai Gao; Meimei Yan; Shuang Zhao; Zheng Yan; Bian Shi; Yanyan Liu
Journal:  J Transl Med       Date:  2022-05-23       Impact factor: 8.440

4.  Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.

Authors:  Raghvendra M Srivastava; Steve C Lee; Pedro A Andrade Filho; Christopher A Lord; Hyun-Bae Jie; H Carter Davidson; Andrés López-Albaitero; Sandra P Gibson; William E Gooding; Soldano Ferrone; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

Review 5.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

6.  NK cells are necessary for recovery of corneal CD11c+ dendritic cells after epithelial abrasion injury.

Authors:  Yuan Gao; Zhijie Li; Nida Hassan; Pooja Mehta; Alan R Burns; Xin Tang; C Wayne Smith
Journal:  J Leukoc Biol       Date:  2013-05-21       Impact factor: 4.962

7.  Tumor immunotherapy: New aspects of natural killer cells.

Authors:  Yangxi Li; Rui Sun
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

Review 8.  Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic.

Authors:  My-Dung Hoang; Sung-Hoon Jung; Hyun-Ju Lee; Youn-Kyung Lee; Thanh-Nhan Nguyen-Pham; Nu-Ri Choi; Manh-Cuong Vo; Seung-Shin Lee; Jae-Sook Ahn; Deok-Hwan Yang; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Chonnam Med J       Date:  2015-04-14

Review 9.  View Point: Semaphorin-3E: An Emerging Modulator of Natural Killer Cell Functions?

Authors:  Abdulaziz Alamri; Abdelilah Soussi Gounni; Sam K P Kung
Journal:  Int J Mol Sci       Date:  2017-11-05       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.